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Summary
The activation of Factor IX by partially purified Factor XI" was
followed by active site titration, gelelectrophoresis and by a
spectrophotometric assay. The assay is based on the finding that
the rate of Factor X activation in the presence of phospholipid
and Caz+ is linear in time and proportional to the amount of
Factor IXu pÍesent and can be determined with the chromogenic
substrate 52222. Conditions were found that allowed complete
activation of Factor IX in human plasma by Factor XIu. The
amount of Factor IX" present in the plasma sample can be
determined with the spectrophotometric assay and is proportional
with the amount of plasma present. In plasma from patients
receiving vitamin-K antagonists reduced Factor IX activity is
found with the spectrophotometric assay, and the new assay
method may be useful in monitoring oral anticoagulant therapy.
Introduction
Factor IX (Christmas Factor, Antihemophilia Factor B)1) is the
zymogen of the serine protease Factor IX.. Factor IX" participates
in the intrinsic pathway of blood coagulation as the enzyme that
activates Factor X, in a reaction accelerated by the nonenzymatic
cofactors, Factor VIII., and phospholipids plus calcium ions (1,
see ref.2 atd 3 for a review).
Bovine and human Factor IX have been purified and charac-
terized, and were found very similar (4-9). Bovine Factor IX is a
glycoprotein with a molecular weight of 55,400 containing a
single polypeptide chain of known amino acid sequence (10).
Factor IX"s with a molecular weight of 45,000 consists of two
* Part of this work was presented by G.T. to the Rijksuniversiteit
Limburg in partial fulfilment of the requirements for the Ph. D. degree.
The chromogenic substrates used in this work were in part donated by
KABI AB, Stockholm, Sweden. Part of this work was presented at the
VIIIth International Congress on Thrombosis and Haemostasis, Toronto,
Canada, July 1981.
1) The nomenclature of the blood coagulation factors used is that
recommended by the Task Force on Nomenclature of Blood Clotting
Zymogens and zymogen Intermediates.
2) The abbreviations used are: pNPGB, p-nitrophenyl-p-
guanidinobenzoate hydrochloride; 52222, N-bemoyl-L-isoleucyl-L-
glutamyl-glycyl-L-arginine-p-nitroanilide hydrochloride; RW-X,
purified. Factor X activator from Russell's viper venom; STI, soybean
trypsin inhibitor.
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polypeptide chains held together by disulÍide bonds. Factor IX is
converted to Factor X"p by Factor XI" in the presence of calcium
ions. During activation two internal peptide bonds Arg1a6 -Alara7
and Arg181-Val182 are cleaved and a carbohydrate rich activation
fragment of molecular weight 10,000 is released (L1,,.12; see
Fig.1) .
The complex of tissue factor and factor VII. also activates
Factor IX, possibly by cleavage of the same two bonds (13,14).
The Factor X activating protease from Russell's viper venom
(RW-X)2), converts Factor IX to Factor IXuo, by cleavage of
only the internal Arg181-yultsz bond, without release of the
activation fragment (12). The calcium requirement and the role of
other metal ions in Factor IX activation by Factor XIu and
RW-X has been investigated (15).
Several methods are used to determine Factor IX and to follow
its activation to Factor IX". These methods are (1-4): 1. A
clotting assay using Factor IX deficient patient plasma (76).2. A
method based on the esterase activity of Factor I[ using
radiolabelled esters, like benzoyl-L-arginine [3H] ethyl ester(17). 3. Method of Nemerson based on the finding that Factor IX
is acid precipitable but its carbohydrate rich activation fragment is
acid soluble. Thus when a Factor IX preparation that is
radiolabelled in the carbohydrate rich fragment is activated, its
conversion to Factor IX^ can be followed by determination of the
release of acid soluble radioactivity (14, 18). 4. Active site
titration. Byrne et al. determined the concentration of Factor IXu
by active site titration with pNPGBz), and reported the kinetic
constants for the reaction between Factor IX" and pNPGB (17).
The methods 2,3 and 4 can only be used with purified Factor IX
or IXu, whereas method 4 requires large amounts of Factor IX".
Only method 1, the clotting assay can be used to determine Factor
IX in plasma.
Our recent work on intrinsic Factor X activation suggested that
a spectrophotometric assay may be feasible. Therefore in the
present study we used the technique of active site titration to
obtain a Factor fX" preparation of known molar concentration
and devised a spectrophotometric assay for purified Factor IX"
and calibrated it with active site titrated Factor IX". The
spectrophotometric assay was used to study the activation of
plasma Factor IX by Factor XI", in order to develop a new
method for the determination of Factor IX in human plasma.
Materials and Methods
Materials. 522222) was purchased from AB Kabi Diagnostica, Stock-
hokn, Sweden; pNPGB was from Nutritional Biochemicals; Russell's
Viper Venom, STI2), egg-yolk phosphatidylcholine and ovalbumin were
obtained from Sigma. DEAE-Sephadex A50, Sephadex G25, G100
and Sepharose 4 B were from Pharmacia. Heparin (unbleached) used to
make heparin agarose (4, 20) was donated by Dr. G. van Dedem,
Diosynth B.V. Oss, The Netherlands. All reagents used were of the
highest grade commercially available.
Plasma. Human reference plasma was citrated platelet poor plasma
obtained from thirty healthy male and female donors. Factor fX and \{[II
t27
deficient plasma was obtained from local patients; Factor WI deficient
plasma was from Merz and Dade, Switzerland.
Coumarin plasma was citrated platelet poor plasma pooled from
patients receiving long term anticoagulant herapy (Marcoumar) and was
provided by Dr. G. Kok, St. Annadal Hospital, Maastricht.
Proteins. Bovine Factor IX was purified as described by Fujikawa et al.
(4). Bovine Factor X1 and X2 were prepared according to Fujikawa et al.
(21). The Factor IX, X1 and X2 preparations were homogenous and pure
as determined by gelelectrophoresis in the presence of sodium dodecyl
sulfate. The specific activities of these preparations, as determined with a
clotting assay, were equal to those reported (4,2I). Factor XIu, used in
this study, was partially pure and isolated from bovine contact product,
made according to Nossel (22) and further purified by heparin-agarose
affinity chromatography as suggested by @sterud et al. (13). Contact
product was applied to the heparin-agarose column (1.5 x 15 cm) in a
buffer mntaining 0.05 M sodium acetate and 0.3 M NaCl at pH 5.5 and
was eluted with a linear gradient of 0.3 to 1.0 M NaCl in 0.05 M
sodiumacetate at pH 5.5. RVV-X was purified from the crude venom as
described by Schiffman et al. (23). Bovine Factor \ was prepared from
bovine Factor X2 using RVV-X according to Fujikawa et al. (24). Bovine
Factor IXu was prepared by incubating Factor IX (2 mglÍnl) at 37" C with
Factor XIu (3S pglml) in a buffer containing 50 mM Tris-HCl' 50 mM
NaCl at pH 8.5 in the presence of L0mM CaCl2 (11). After 60min
incubation the reaction mixture was brought to 1"5 mM EDTA and
20 mM benzamidine and apptied to a column of DEAE-Sephadex 450
(1.5 x 30 cm) in 50 mM Tris-HCl, 50 mM NaCl and 20 mM benzamidine
at pH 7.9. Factor D(u was eluted with a linear gradient of 50 mM to
400 mM NaCl (2 x 500 ml) in 50 mM Tris-HCl,zO mM benzamidine at
p}I7.9.
Phospholipids and phospholipid vesicle preparation. Brain phos-
phatidylserine was prepared as described by Sanders (25). Single bilayer
vesicle solutions of a mixture of brain phosphatidylserine and egg-yolk
phosphatidylchohte (25175 wlw) were prepared according to de Kruijff et
al. (26) by sonication for 10 min in 50 mM Tris-HCl, 175 mM NaCl at
pH7.9. Sonication was performed using a MSE MarkII 150 Watt
ultrasonic disintegrator set at 10 miqons peak to peak amplitude. After
sonication no pH adjustment was needed.
Actíve site titration of Factor IXo. Titration experiments were con-
ducted at 37" C in thermostated cuvettes in an Aminco DW-2a spec-
trophotometer set in the split beam mode at 405 nm. In a typical
experiment the sample cuvette contained 40 pg Factor I\ in 800 pl
0.05 M sodium veronal buffer (pH 8.3) in the presence of 20 mM CaCl2.
The reference cuvette contained 800 pl 0.05 M sodium veronal buffer and
20 mM CaCl2. After an appropriate time to allow for temperature
equi.libration 5 p,l of a 0.02 M solution of pNPGB in dimethylformamide
wàs simultaneously added to the sample and the reference cuvette using
^ ^  I c a r b o x y g l u t a m i c  a c i d  r e s i d u e s
oo
T  T  c a r b o h y d r a t e  a t t a c h e d
Fig.l Diagram of bovine factor IX. Factor IX is composed of a single
polypeptide chain of 416 aminoacids. The carboxlterminal part of the
molecule is homologous with trypsin, with the active site serine residue at
position 366. Twelve 1-carboxyglumatic acid residues are located among
the first 40 aminoacids from the N-terminus. Four asparaginyl residues
have carbohydrate attached with total molecular weight of 8,100.
Activation by Factor XIu, is indicated by arrows, and involves cleavage
between 61gr46-61^rat residues and between Arg181-yu1taz. The peptide
of 34 aminoacids containing most of the carbohydrate is released giving
rise to Factor I\p. The tight and heavy chains are connected by S^-S
bond(s). RVV-X activation results in Factor IX"o, with only the Arg181-
Val182 bond cleaved (Data from Katayama et al., 10).
r28
matched micropipettes. Under these conditions the presteady state part of
the reaction is completed in about 6 min. \Vhen Factor IX at comparable
concentrations is allowed to react with pNPGB no burst of p-nitrophenol
production is observed. However, Factor IX gives a low steady state
production of p-nitroPhenol.
Theory of titation. When a serine esterase is active site titrated with
pNPGB, a rapid burst of p-nitrophenol is observed followed by a very
ilow or negligible steady state production of p-nitrophenol. Bender et al.
(27,28) have derived kinetic equations for this process according to a
three-step mechanism.
K k 2 k 3
E+pNPGB -: E.NPGB + E-GB + E*GB.
+NP
Here E is the enzyme, pNPGB is the substrate, E. NPGB is the
enzymesubstrate complex, E-GB is the guanidinobenzoyl enzyme that
results from the stoichiometric reaction of enzyme with substrate libera-
ting 1. eq of p-nitrophenol (NP) and GB is the free p-guanidinobenzoate
that results from the deacylation of the E-GB complex.
Factor IX" was reacted with various concentrations of pNPGB and the
appearance of p-nitrophenol in time recorded. The data weÍe treated
aócording to Bender et aL. (27,28) to obtain the various parameters' The
deacylation Íate constant k3 was determined according to Chase and Shaw
(29) by isolation of the acylenzyme intermediate and following the
reappearance of enzyme activity in time with the spectrophotometric
assay (see below). Because of the similarity in methods and results we
present the final results together with those from ref.19 in Table 1. An
extensive account of the method can be found in rcf.27,28' 19.
Spectrophotometric assay for Factor IXo. Factor IXu converts Factor X
to Factor \ in the pÍesence of negatively charged phospholipids and
calcium ions. Conditions can be chosen such that the rate of Factor Xu
formation is constant in time and proportional to the amount of Factor IXu
present in the reaction-mixture (1; see also Results Section). Sonicated
phospholipid vesicles 0.5 mM, in 50 mM Tris, 175 mM NaCl pH 7.9 were
brought to 50 mM CaCl2 and incubated for 10 min at37" C.0'1 ml of the
vesicle-calcium suspension is added to 0.3 ml of a mixture containing
0.5 nmol of Factor X, 50 mM Tris-HCl p}J7.9,175 mM NaCl and 1 mg/
ml ovalbumin. This mixture was incubated for 4 min at 37" C and Factor
X activation was started by addition of 0.1 ml of the Factor IX. sample to
be analysed. After L0 min at 37'C, Factor Xu formation was stopped by
transferring 0.4 ml to the cuvette with 1.6 ml of a buffer containing
50 mM Tris-HC1pH7.9,175 mM NaCl, 20 mM EDTA, 24I VN[S2222
and 0.5 mg/ml ovalbumin. From the absorbance change at 405 minus
500 nm measured on an Aminco DW-2a spectrophotometer in the dual
wavelength mode and a calibration curve, made by measuring the rate of
52222 hydrolysis with known amounts of active site titrated Factor Xu
(30), the amount of Factor )q present in the reaction mixture can be
calculated.
Gelelectrophoretic analysis of Factor IX activation. Gelelectrophoresis
in the presence of sodium dodecyl sulfate was carried out as described
by Laemmli (31) with gels containing LIVo acrylanide, 0'27Vo
N,N3-methylenebisacrylamide and 0.IVo sodium dodecylsulfate. To fol-
low the activation of Factor IX by Factor XI" or by RW-X' aliquots of
the activation mixture (1.0 ul) were diluted 30 fold in 2% sodium dodecyl-
sulfate and were kept for 3 min in a boiling lvaterbath' 5Vo Mercap'
toethanol was present in disulfide reduced samples. 50 pl of each sample
was applied to a gel. After electrophoresis, gels were removed from the
tubes, and stained and destained according to Fairbanks (32). Finally' the
gels were scanned on a Gilford Model 250 spectrophotometer.
The amount of protein present in the gel bands was estimated with
calibration curves obtained by running known amounts of Factor IX and
Factor IXu on unreduced and reduced gels. After sfainilg, destaining'
scanning and determining the surface area of the peakscans, calibration
curves were obtained that were used to quantitate Factor IX, the
activation intermediate and Factor IXu present in the gels (reduced and
unreduced) that were run to follow Factor IX activation.
Results
Aaive Site Titration of Factor IXo
Ideal active site titrants for proteolytic enzymes are compounds
that bind to and are rapidly cleaved by the enzyme. After
t 4 6 - Í 4 7  t 8 ' t - t 8 2
A r g - A l a  a r g - V a l
cleavage, one part of the titrant remains bound to the enzyme
thereby blocking the active site whereas the other part usually
carrying a chromophoric group like p-nitrophenol is released and
can be measured spectrophotometrically. Quantitation of the
enzyme is simple since from the amount of chromophore released,
the molar concentration of enzyme can be calculated (27).
The compound pNPGB has been used for active site titration
of trypsin and the trypsinlike enzymes, thrombin and Factor X"
(27 , 30). Its usefulness for Factor IXu was assessed by determina-
tion of the kinetic parameters for the reaction. After completion
of this work Byrne et al. (19) reported the kinetic parameters,
determined under slightly different reaction conditions. Therefore
in Table 1, we only show our final results, together with the data
of Byrne et al. (19). The results are in good agreement and justify
the use of pNPGB as an active site titrant for Factor IXu.
Different preparations of Factor IXu were active site titrated
with pNPGB and dependent on the preparation 0.70-0.95 active
sites/mole of Factor IXu were found. The molar concentration of
Factor IXu was calculated from the absorbance at 280 nm using
A\{i, : 14.3 (1.t) and a molecular weight of 46,000. For Factor
IX a molecular weight of 56,000 and a A!P, : Í4.9 was used
(1 1) .
When Factor IX was activated with either Factor XIu or
RW-X and active site titration was carried out directly with a
sample from the activation mixture, 0.95-1.00 active sites/mole
of Factor IX were generated. Apparently some loss of active sites
may occur during further IXu purfication. The results also indicate
that cleavage of Factor IX by Factor XIu or by RW-X results in
the formation of one active site per molecule of zymogen.
Spectrophotometric Assay for Factor IXo
No specific chromogenic substrate for Factor IXu is presently
available. Flowever, in a recent study of the kinetics of Factor X
activation by Factor IX" we have shown that the rates of Factor \
formation in the presence of phospholipids and calcium ions but
without Factor VIII. were sufficiently high to be measured with
the chromogenic substrate 52222 (l). Under these conditions, the
rate of Factor Xu formation is linear in time and as shown in Fig. 2,
the rate is proportional to the amount of Factor IXu, at least up to
4 pglml of Factor IX".
The assay was not influenced by the presence of Factor XI".
Factor XIu in concentrations as used in the assay did not activate
Factor X and Factors IX" and XI" did not hydrolyse 52222
directly.
Activation of Bovine Factor IX by Factor XIo
Bovine Factor IX was incubated with Factor XIu in the
presence of calcium ions (11). At various times samples were
taken and the molecular changes studied with polyacrylamide gel
electrophoresis with and without reduction (Fig.3A, B). During
activation an intermediate appears rapidly, that is converted more
slowly to the end product. From the work of Lindquist et al. (I2)
it can be concluded that the intermediate represents Factor IX
cleaved at the Arg1a6-Ala1a7 site, which is later cleaved at Arg181-
Val182 to give Factor IX"p. The amounts of protein present in the
various bands on the gels were estimated as described in the
Materials and Methods section, and are shown in Fig. 3 C.
Reaction samples were further examined for presence of active
sites titratable with pNPGB and for Factor IXu activity deter-
mined in the spectrophotometric assay. The results together with
those from the gels are shown in Fig.3D. The appearance of
double cleaved Factor I\ on gels; of active sites titratable with
pNPGB and of enzymatic activity towards Factor X is synchro-
nous. Therefore, appearance of the active site and of enzyme
activity are associated with the Arg-Val cleavage and no activity is
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Fig.2 Cahbration curve of the rate of factor Xu formation with varying amounts of active site titrated bovine Factor IXu. Factor IXu was incubated with
puriÏied Factor X, phospholipid vesicles and Ca2+ and the amount of Factor I formed after 10 min was determined with the chromogenic substrate
52222. Conditions were as described in Materials and Methods.
Fig.4 Time course of Factor IX activation in human plasma by Factor XI.. Human reference plasma, 20 pl, was incubated with varying amounts of
partially purified Factor XI" in a reaction mixture of 1 ml containing 50 mM Tris-HCl, pH 7.9, 175 mM NaCl, 10 mM CaCl2 and 0.5 mglml ovalbumin.
After the time intervals indicated in the figure samples of 0.1 ml were added to 0.4 ml of a Factor X activation mixture containing Factor X, Ca2+ and
phospholipids as described in the Methods section and the amount of Factor >q present after 10 min was calculated as in Fig.2. Using the calibration
curve of Fig. 2, the amount of bovine Factor IX, that would produce this amount of Factor Xu was calculated. From this amount the amount of factor IXu
present in the plasma Factor IX activation mixture was calculated. Thus, one arbitrary unit of plasma Factor I[, as indicated at the ordinate, is equal to
the activity of 1 pmole of purified bovine Factor IX" in the spectrophotometric assay. The concentrations of Factor Xluusedwere: A-^ 3 pg/ml,
O-O 1.5 trrg/ml, l-l 0.751t9/ml.
Fig. 5 Cakbration curves of Factor IX in human reference plasma, in coumarin plasma and in plasma from patients congenitally deficient in Factor VII,
VIII or IX. Varying amounts indicated in the figure of different human plasmas were activated with 1.5 pg Factor XIu in a final reaction volume of 1 ml
containing 50 mM Tris-HClp}l 7.9,175 mM NaCl, 10 mM CaCl2 and 0.5 mg/ml ovalbumin. After 25 min incubation at37o C, a sample was taken and
the amount of Factor IX" present was determined as described in the legend of Fig.4. O-O Human reference plasma, l-I Factor VII deficient
plasma, -^ Factor VIII deficient plasma, !-n Factor IX deficient plasma, O-O Coumarin plasma.
pmol  lXa  /ml
Fig.2
I29
Tabte I Kinetic constants for the reaction of bovine Factor IXu with
pNPGB. Active site titration of bovine Factor IXu was carried out as
àescribed in Materials and Methods. The calculation of kinetic parameters
and rate constants is based on the titration theory of Bendet et aL' (27 '
28).
Kinetic parameters This work BYrne et al. (1'7)
20 mM ca2+ L0 mM Ca2+
37"  C 30 'c
520
0 .13
1
13,000
0.04
When the amount of plasma present in the reaction mixture for
Factor IX activation was increased from 40 till 100 pl plasma, the
increase in Factor IX" activity was slightly less than proportional
and with 200-500 pl per ml only a small increase in Factor IXu
activitywasfound.Thisphenomenonmaybedr'etoinactivation
or inhibition of Factor XI" or Factor IXu and was not further
investigated.
Theiefore a standard Factor IX determination in plasma is
carried out as described in the legend of Fig' 5 with 20 pll of
plasma per ml reaction mixture. This will result in an absorbance
itrung" of 0.0081 À A405/min. For spectrophotometers less
,"r,riliu" than our Aminco DW 2a, higher absorbance changes
may be required. These can be obtained by prolonging the Factor
X áctivation step or by transfer of larger amounts of the Factor Xu
reaction mixture to the cuvette.
A major condition for the assay is absence of interference by
other plasma components. Therefore several control experiments
*"r" àon" to veiify that the Factor X activating activity that
K. (pM)
kz (5-')
k3 (10s x 5-1)
k2lk3
K- app (pM)
r87
0.056
3
1,875
0.1
Table 2 Comparison of clotting and spectrophotometric assays for
Factor IX in human plasmas. The data obtained with the spec-
trophotometric assay were calculated from the results shown in Fig'5'
Thà Factor IX content of the same plasmas lvas determined in a one-stage
clotting assay using Factor IX deficient plasma (16)'
Plasma Clotting assay Spectrophotometric assay
Normal reference
Factor IX deficient
Factor VII deficient
Factor VIII deficient
Coumarin
1.00Vo
< 2Vo
6J "/o
76%
26%
100Vo
< lVo
88Vo
80Vo
3 1 %
available in the intermediate' This is in agreement with the finding
that the intermediate lacks coagulant and esterase activity (L2)'
When Factor IX is converted by RW-X to Factor IXuo' the
same number of active sites were found (19)' Subsequent
conversion of Factor IXuo to Factor IXup with Factor XI" did not
increase the active site cóntent (data not shown). Nevertheless,
Factor IXuo was reported to have half the specific activity of
Factor IX"i*in a clotting assay and in an esterase.assay with tosyl-
L-argininË"methyl ester (12). Since the active site content is the
,u-"-it is concluded that the kinetic parameters for the substrate
aÍe less favourable when Factor IXuo is the enzyme'
Acrtvarton of Factor IX in Human Plasma
Our approach to assay Factor IX in plasma-was: a' to convert
all FactoiiX in a plasma sample to Factor IX" by adding purified
Factor XIu; b. to lncubate the plasma sample containing Factor
IX" with Factor X, Ca2+ and phospholipid.c' to measure the
amïunt of Factor Xu formed in the latter incubation mixture with
the chromogenic suLstrate 52222; d. to calculate the amount of
Factor IX. present in the plasma sample from the rate of Factor
X" formation and a calibration curve made with known amounts
of Factor lX" (see Fig.2).
In Fig.4 time courses are shown for the generation of Factor
IXu in É.r-utt plasma' When 20 pl of plasma is incubated at
10'mM Ca2+ and 0.75 pg of Factor XIu in a reaction volume of
1 ml, a plateau level of Factor IXu activity is reached after 30 min
(Fig-a, squares). At twofold, respectively fourfold higher Factor
itj cottcónttadons the plateau level remains-approximately.the
sarire, but is reached aÍter 20, respectively 10 min of activation.
Using these reaction conditions, varying amounts of plasma
(S-+ó pf) were incubated Íot 25 min with 1'5 pg/ml Factor XI"'
ihe results (Fig.5, closed circles) indicate that the Factor IX"
activity that is gónerated is proportional to the amount of plasma'
From these eiperiments we conclude that under our reaction
conditions a[ Fàctor IX in plasma can be converted to Factor IXa'
130
Fig. j Activation of Factor IX by Factor XIu, as Ïollowed by gelelec-
ffihoresi., active site titration and by a spectrophotometric assay for
faËtor IX". Factor IX (1.5 mglml) was activated with partially purified
nu"to. X" (30 pglml) in a buffer containing 50 mM Tris-HCl' 50 mM
NaCl pH S5, :i C. After the time intervals indicated, samples were
taken ànd active site titrated, assayed for Factor IXu and applied to the
gels. The gels were run, stained, destained, scanned and the protein
it"."rrri" tïe bands quantitated as described in the Methods section' 
(A)
'Gel 
pattern of Factoi IX activation, without reduction; (B) as (A)' with
."duàtiorr, (Int, denotes the Factor IX activation intermediate' subscripts
h and 1, heavy and light chain, cf. Fig' 1); (C) Data obtained from gel
scanning: O a, amount of Factor IXu present in the sample; O-O'
u-ooot of Factor IX in sample; !-tr' amount of intermediate present
in sample. (D) Time courie of Factor IX activation determined by:
O-O, gei scunnitrg; !-r], active site titration; O-O, spec-
trophotometric assay for factoÍ IXu'
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appears in plasma during incubation with Factor XIu and Ca2+, is
due only to Factor IXu.
By omitting Factor X from the assay it was found that during
Factor IX activation in plasma no significant plasma Factor X
activation occurs, since the amount of Factor Xu formed is
negligible compared to the amounts of Factor X" formed by
Factor I\ in the Factor X activation reaction. Therefore any
Factor Xu that may have formed during plasma activation did not
interfere qrith our spectÍophotometric assay.
Fig.5 (open squares) shows that in Factor IX deficient plasma
no Factor IX", nor other Factor X activators are formed.
Apparently Factor VII1u.y, another Factor X activator does not
contribute to Factor X activation in our assay. Indeed (closed
squares) Factor VII deficient plasma yields nearly the same level
(887o) oï Factor X activating activity (Factor IX) as human
reference plasma.
Factor VIII. increases the V-* of Factor Xu formation by
Factor IX" (1). To rule out Factor VIII" involvement, Factor VIII
deficient plasma was activated and found to contain SOVo of the
Factor IX in normal pooled reference plasma (triangles). When
reference pool plasma was first clotted with thrombin, a treatment
known to destroy Factor VIII" activity, and then activated with
Factor XIu and Ca2+, the amount of Factor IXu formed in our
assay lvas equal to that found in the original plasma. Therefore
under our conditions, the spectrophotometric assay is not
influenced by Factor VIII..
In Fig.5, it is further shown that plasma pooled from patients
receiving coumarin, contains 3tVo oï Factor IX in reference
plasma when measured with the spectrophotometric assay (open
circles). This suggests that the spectrophotometric assay like a
clotting assay discriminates between normal Factor D( and the
abnormal (descarboxy) Factor IX molecules that are present in
coumarin plasma (compare Table 2).
Table 2 shows the Factor IX content of various plasmas
determined vsith the spectrophotometric assay (Fig.5) and with
the coagulation assay using Factor IX deficient plasma. The
slightly lower Factor IX content of the Factor VII and Factor VIII
deficient plasmas, also appears when Factor IX is determined in a
clotting assay and may be due to normal variation in Factor IX
content of plasma.
Discussion
The kinetic constants reported here for the reaction of Factor
IX. with pNPGB are identical to those of Byrne et al. (19), and
indicate that pNPGB is a suitable active site titrant for Factor IXu.
Our work on the kinetics of Factor X activation (1), allowed us
to devise a spectrophotometric assay for Factor IXu. A linear
relationship was found between the amount of active site titrated
Factor D(u and the initial rate of Factor X activation, measured in
the presence of phospholipids (25Vo phosphatidylseine andTíVo
phosphatidylcholine) and calcium ions. The conversion of Factor
IX to Factor IX"B with Factor XI" and Caz+ was followed with the
spectrophotometric assay, with active site titration and with
polyacrylamide gel electrophoresis. The results confirm the cleav-
age pattern of Factor IX and the accumulation of the intermediate
as first found by Lindquist et al. (12). The intermediate without
coagulant or esterase activity is also unreactive towards pNPGB.
This is not simply due to presence of the activation fragment per
se because RW-X cleaved Factor IXuo is an active enzyme.
Cleavage at Arg181-Val182 is simultaneous with appearance of
active sites towards pNPGB and enzymatic activity towards
Factor X. Apparently, cleavage of the Arg-Val bond is essential in
formation of the active site.
Factor IXuo and Factor IXu6 have the same number of active
sites (19) but Factor IXuo has twice the clotting activity of Factor
IX" (12). The kinetic parameters of the two enzymes for ester
hydrolysis in the presence oÍ Ca2+ differ only slightly (19). It
would be of interest to compare the kinetic parameteÍs of both
enzymes in Factor X activation.
In this paper we present a spectrophotometric assay for Factor
IXu, based on the fact that under suitable conditions the rate of
Factor X activation is proportional to the Factor IXu concentra-
tion. The assay can be used to determine Factor IXu in samples
from activation mixtures containing purified Factor IX or in
samples from plasma after quantitative activation of Factor IX by
incubation with purified Factor XIu and Ca2+.
A major requirement in an assay for plasma clotting factors is
to exclude the effects of inhibitors and activators in plasma. Fig.5
shows that the amount of Factor IXu generated is proportional up
to a plasma concentration of 40 pl per ml of Factor IX activation
mixture. Usage of larger amounts of plasma (defibrinated with
thrombin to prevent clotting) results in incomplete activation of
Factor IX. This might be due to the influence of protease
inhibitors. Possible interference of the spectrophotometric assay
by Factors VIII. and VII. was excluded by the finding that
plasmas congenitally deficient in either of these two factors
contain about the same amount of Factor IX as normal reference
pool plasma. The slightly lower Factor IX content is also found
with the clotting assay, and can be ascribed to individual
variations (Table 2). The finding that no Factor IX" activity arises
during activation of Factor IX deficient plasma, further excludes
interference in the assay by Factor VII. or by another unknown
Factor X activator.
Factor IX is one of the vitamin K dependent coagulation
factors and plasma from patients on oral anticoagulant therapy
contains descarboxy proteins, lacking the y-carboxy glumatic acid
residues that are involved in Ca2+ dependent binding to the
negatively charged phospholipid surface (34). Coumarin plasma
with 267o Factor IX in a clotting assay, has Factor IX 3I% of
normal in the spectrophotometric assay. Apparently, the des-
carboxy Factor IX molecules present in coumarin plasma do not
participate in the reactions of the assay. This is to be anticipated
since the activation of Factor X by Factor IXu takes place at a
phospholipid surface and diminished Caz+ dependent binding of
descarboxy Factor IXu will lower the rate of Factor X activation
when less lipid bound enzyrne is available.
In addition or alternatively, it may be possible that descarboxy
Factor IX cannot be activated to descarboxy Factor IXu by Factor
XI". In a comparable enzymatic reaction it was found that
descarbory Factor X is very slowly converted to descarbory
Factor Xu by RVV-X (35).
The spectrophotometric assay for Factor IX described here
may prove to be useful for determination of Factor IX in patient
plasma. The assay incorporates a phospholipid dependent activa-
tion reaction, responds to descarboxy Factor IX, and may find
application in evaluation of oral anticoagulant therapy.
Addendum
A paper on the clinical application of the Factor IX method
reported here is in press. Title and authors: "Use of chromogenic
peptide substrates in the determination of clotting Factors II, VII,
IX and X in normal plasma and in plasma of patients treated with
oral anticoagulants.< M. P. van Dieijen-Visser, J. van Wersch, P.
J. Brombacher, J. Rosing, H. C. Hemker and G. van Dieijen.
Haemostasis.
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